澳门葡京网赌游戏将在2015年全球药品大会上公布其广泛的肾脏药物组合的新数据th 欧洲肾脏协会-欧洲透析和移植协会(ERA-EDTA)大会, 2020年6月6日至9日.
将提交的20份摘要，包括4份口头报告，将包括关于 Lokelma (环硅酸锆钠)，罗沙司他和 Farxiga (dapagliflozin) across different st年龄s of chronic 肾脏 disease (CKD) and 澳门葡京网赌游戏’s ongoing commitment to exploring treatment options across the full continuum of renal care.
路德浮标, 执行副总裁, 澳门葡京赌博游戏事业部, 他说:“全世界有超过7亿人患有慢性肾脏疾病, 进行性疾病, 目前尚无治疗方法. 澳门葡京赌博游戏在ERA-EDTA的数据显示了该疾病所有阶段的进展, 预防和保护, 减缓病情发展和控制严重并发症.”
推进CKD患者高钾血症的治疗，包括透析患者
澳门葡京网赌游戏将提供一系列的子分析 Lokelma Phase IIIb DIALIZE trial reinforcing the effectiveness of this medicine to man年龄 hyperkalaemia in patients with CKD on haemodialysis, 不考虑性别等因素, 国家, 年龄, 体重或疾病严重程度.1,2
高钾血症是慢性肾病患者常见的并发症, 并可能导致严重的心律失常, 心脏骤停, 麻痹和虚弱, 甚至死亡.3,4 除了DIALIZE, real-world evidence will be presented showing that the number of cardiovascular (CV) or renal comorbidities increases the risk of hyperkalaemia in patients with CKD, 强调有效预防和治疗的必要性.5
评估贫血性CKD患者治疗的有效性和安全性
Results will be presented from a Phase III trial assessing roxadustat versus darbepoetin alfa for the treatment of anaemia in CKD patients not on dialysis. 还将介绍另一项III期试验的预先指定分析, assessing the ophthalmological/retinal effects of roxadustat in the treatment of anaemia in dialysis-dependent CKD patients compared to darbepoetin alfa.6
澳门葡京网赌游戏 and FibroGen are collaborating on the development and commercialisation of roxadustat for the potential treatment of anaemia in the US, 中国以及美洲和澳大利亚/新西兰的其他市场, 以及东南亚. Astellas and FibroGen are collaborating on the development and commercialisation of roxadustat for the potential treatment of anaemia in territories including Japan, 欧洲, 独立国家联合体, 中东和南非. 安斯泰来赞助了这两项试验，并将提供这些数据.
有现实证据表明CKD患者需要改进治疗方法
澳门葡京网赌游戏继续研究CKD早期干预的机会, 因为在全球范围内，这种疾病的诊断不足, 患者可能直到病情恶化才意识到自己患有这种疾病.7,8
在大会上, new analyses of real-world data on type-2 diabetic and non-diabetic patients with CKD will be presented which demonstrate a need for additional treatment options to improve adverse renal, CV和死亡率结果，并减轻患者和卫生保健系统的负担.9,10
此外, a real-world analysis of the DISCOVER-CKD trial will be shared showing a high prevalence of type-2 diabetes and high blood pressure in patients with CKD, 表明这一群体的高合并症负担，新疗法可能对其有益.11
关键的澳门葡京网赌游戏报告和其他值得注意的摘要在57th ERA-EDTA大会包括:
第一作者 |
摘要标题 |
Lokelma
|
|
汉姆在D. |
Sodium Zirconium Cyclosilicate Corrects Hyperkalaemia Within 72 hours Among Outpatients With Severe Hyperkalaemia (Baseline Serum Potassium ≥6 mmol/L) Regardless of 肾 Function Level or RAASi Use: Post Hoc Subgroup Analysis of a Phase 3 Trial |
McCafferty K. |
Subgroup Efficacy Analysis of Sodium Zirconium Cyclosilicate (SZC) in Hyperkalaemic Haemodialysis Patients in the DIALIZE Study |
佩尔松F. |
一个随机, 双盲, Placebo-Controlled Multicenter Study of the Effects of 12 Weeks of Sodium Zirconium Cyclosilicate (ZS-9) on Albuminuria (UACR) in Patients with Type 2 Diabetes and Hyperkalemia |
福特、米. |
Effectiveness of Sodium Zirconium Cyclosilicate (SZC) in Haemodialysis Patients with Severe Hyperkalaemia in the DIALIZE Study |
Puchades, M.J. |
KEEP ON(保持最佳钾控制下的RAAS抑制处理). Design of a Clinical Trial of Using Sodium Zirconium Cyclosilicate for keeping RAAS Inhibition and/or MRAs in Patients with Chronic Kidney Disease and Congestive Heart Failure History |
罗杰,年代.D. |
Sodium Zirconium Cyclosilicate Increases Serum Bicarbonate Concentrations Among Patients with Hyperkalaemia: Results from Three Randomized, 多剂量, 安慰剂对照试验 |
Avesani C.M. |
Healthy K-Rich Diet in Chronic Kidney Disease (CKD) Patients Using Sodium Zirconium Cyclosilicate (SZC) to Control Hyperkalemia: A Feasibility Study (HELPFUL)
|
Roxadustat
|
|
赛帕,Y. |
Ophthalmological Effects of Roxadustat in the Treatment of Anaemia in Chronic Kidney Disease Patients on Dialysis: Sub-Analysis of a Phase 3, 随机, 双盲, 主动比较器转换研究 |
Barratt J. |
罗沙司他治疗非透析慢性肾病患者贫血:3期研究, 随机, 非盲, Active-Controlled研究 |
格林纳达尔-凡德门特博士. |
严重肾功能损害或终末期肾病对罗沙他特药代动力学和药效学的影响, 口服缺氧诱导因子脯氨酸羟化酶抑制剂
|
Farxiga
|
|
Olufade T. |
Characterization of a DAPA-CKD-Like Population Using a Contemporary US Healthcare System: Cohort Characteristics and Clinical Outcomes |
Olufade T. |
使用当代美国医疗队列的dapa - ckd样人群的医疗资源利用和成本
|
心血管、肾 & 代谢(CVRM): CKD
|
|
洛佩斯,M.B. |
A Real-world Longitudinal Analysis of Anemia Treatment Prescriptions in Non-Dialysis-Dependent Chronic Kidney Disease Patients, CKDopps研究 |
徐,M. |
估计英国慢性肾脏疾病(CKD)的负担:两种健康经济政策分析方法的比较 |
徐,Y. |
肾性贫血患者透析前血红蛋白目标达到和透析后结局:一项全国性研究 |
加西亚·桑切斯，J.J. |
Clinical Characteristics and eGFR and UACR Distribution According to the 2012 KDIGO CKD Classification: A Report from the US DISCOVER CKD Cohort |
亚历山大,.F. |
慢性肾脏疾病贫血患者治疗偏好的定性研究 |
魏氏,E. |
补充因素 Bb 和因素 C4d IgA肾炎和IgA血管炎
|
CVRM:高钾血症
|
|
Hoskin L. |
The Association Between Hyperkalaemia Risk and 心血管 and 肾 Comorbidities in a Large Real-world Cohort of CKD Patients |
Tafesse E. |
英国临床实践中慢性肾病患者高钾血症复发的模式 |
All ERA-EDTA 2020 Virtual Congress abstracts will be made available online on Friday 2020年6月5日 in an abstract supplement to be published with the June issue of the 肾透析移植杂志
澳门葡京网赌游戏在crvrm
心血管，肾脏和代谢 (CVRM) together forms one of 澳门葡京网赌游戏’s three therapy areas and is a key growth driver for the Company. 通过遵循科学来更清楚地了解心脏之间的潜在联系, 肾脏和胰腺, 澳门葡京网赌游戏正在投资一系列药物，以保护器官，并通过减缓疾病进展来改善结果, 减少风险和处理合并症. The Company’s ambition is to modify or halt the natural course of CVRM diseases and potentially regenerate organs and restore function, by continuing to deliver transformative science that improves treatment practices and cardiovascular health for millions of patients worldwide.
澳门葡京网赌游戏
澳门葡京网赌游戏(LSE/STO/NYSE: AZN)是一家全球性制药公司, 以科学为主导的澳门葡京赌博游戏公司，专注于发现, 处方药的开发和商业化, 主要用于治疗肿瘤等三个治疗领域的疾病, 心血管、肾 & 新陈代谢和呼吸 & 免疫学. 总部设在剑桥, UK, 澳门葡京网赌游戏在100多个国家开展业务，其创新药物被全球数百万患者使用. 请访问 澳门葡京网赌游戏.com 并在推特上关注公司 @澳门葡京网赌游戏.
联系人
参考文献
- McCafferty K等. Subgroup Efficacy Analysis of Sodium Zirconium Cyclosilicate (SZC) in Hyperkalaemic Haemodialysis Patients in the DIALIZE Study. 第57届ERA-EDTA虚拟大会，2020年6月7-9日.
- 福特等. Effectiveness of Sodium Zirconium Cyclosilicate (SZC) in Haemodialysis Patients with Severe Hyperkalaemia in the DIALIZE Study. 第57届ERA-EDTA虚拟大会，2020年6月7-9日.
- Bansal S, Pergola PE. 透析患者高钾血症的当前管理. 肾Int代表 2020.
- 美国心脏协会. 第10部分.1:危及生命的电解质异常. 循环 2005; 112(24_suppl):IV-121-IV-125.
- 霍斯金等. The association between hyperkalaemia risk and cardiovascular and renal comorbidities in a large real-world cohort of CKD patients. 第57届ERA-EDTA虚拟大会，2020年6月7-9日.
- Sepah Y等. Ophthalmological Effects of Roxadustat in the Treatment of Anaemia in Chronic Kidney Disease Patients on Dialysis: Sub-Analysis of a Phase 3, 随机, 双盲, 主动比较器转换研究. 第57届ERA-EDTA虚拟大会，2020年6月7-9日.
- 国家肾脏基金会. 肾脏疾病:基础[引证26].05.20]. 可从:URL: http://www.肾脏. org/news/newsroom/factsheets/KidneyDiseaseBasics.
- 国家肾脏疾病教育计划. 慢性肾脏疾病:什么是慢性肾脏疾病? [引用26.05.20]. 可从:URL: http://www.的趋势.国家卫生研究院.gov /信息/肾脏疾病/ chronic-肾脏-disease-ckd / what-is-chronic-肾脏-disease.
- Olufade等. Characterization of a DAPA-CKD-like population using a contemporary US Healthcare System: Cohort characteristics and clinical outcomes. 第57届ERA-EDTA虚拟大会，2020年6月7-9日.
- Olufade等. 使用当代美国医疗队列的dapa - ckd样人群的医疗资源利用和成本. 第57届ERA-EDTA虚拟大会，2020年6月7-9日.
- 加西亚·桑切斯JJ等. Clinical characteristics and eGFR and UACR distribution according to the 2012 KDIGO CKD classification: A Report from the US DISCOVER CKD Cohort. 第57届ERA-EDTA虚拟大会，2020年6月7-9日.